[Experiment and clinical application of targeting treatment with adriamycin magnetic albumin microspheres in human gastric carcinoma].
OBJECTIVE
To study the pharmacokinetics in experimental animals and observe the concurrent anticancer effects in human advanced gastric cancer as an adjuvant chemotherapy, when adriamycin magnetic albumin microspheres (ADM-MAM) were combined with external static magnetic fields.


METHODS
The drug concentration of targeting tissues in the animals and the stability of ADM-MAM in human gastric juices were determined. Clinical and histopathological changes were observed in 55 cases of advanced gastric carcinomas after targeting treatment.


RESULTS
The peak concentrations of the targeting tissue were highest after ADM-MAMs were administered for 2 hours and remained at the high level for a long time. ADM-MAM maintained its stability in human gastric juices. Targeting treatment improved the patients' symptoms, raised the rated of tumor resection, prolonged patients' lifetime, and enhanced histopathological effects (P < 0.01).


CONCLUSIONS
The administration of ADM-MAM combined with the external static magnetic fields is effective for targeting location and is of clinical value as a preoperative adjuvant chemotherapy for human advanced gastric carcinoma.
Tao
K
K
Department of General Surgery, Union Hospital, Tongji Medical University, Wuhan 430022.
Chen
D
D
Wang
G
G
Bai
Z
Z
Lu
X
X
Tian
Y
Y
Wu
Z
Z
Hu
F
F
Nie
X
X
D000293:Adolescent; D000328:Adult; D000368:Aged; D000418:Albumins; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D008280:Magnetics; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D051381:Rats; D017208:Rats, Wistar; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000628:therapy; D016896:Treatment Outcome
D000418:Albumins; D000970:Antineoplastic Agents; D004317:Doxorubicin